Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccine (MART-1, gp100, Tyrosinase) in Metastatic Melanoma
NCT00001685Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 1997
- Modality
- Whole Cell Cancer Vaccines, Peptides, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of mart-1 + gp100 + tyrosinase in melanoma, sponsored by National Cancer Institute. Started Nov 1997; status: completed.
02
Drugs
mart-1 + gp100 + tyrosinase
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00001685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001685.